Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs Abstract #156

Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Aim(s): To evaluate toxicity and therapeutic efficacy (response and survival) of PRRT in radioiodine-nonavid/therapy refractory thyroid cancer patients.
Materials and methods: Fifteen iodine-nonavid/radioiodine therapy refractory thyroid cancer patients (mean age 60 yrs, M:F 7:8) were treated with PRRT using Y-90 and/or Lu-177 SMS analogs (DOTA-TATE/-TOC or -NOC). All patients were heavily pretreated and presented with progressive disease at follow-up. The dose range per cycle for Y-90 was 2500–5000 MBq, and 3500 – 7500 MBq for Lu-177. Primary histology: follicular cancer (n=4), medullary thyroid cancer (n=7), Hurthle cell carcinoma (n=3), and mixed carcinoma (n=1). Ga-68 somatostatin receptor PET/CT was used to determine the somatostatin receptor density in the metastastes and in recurrent tumor lesions and to assess treatment response. PRRT was performed under strict nephroprotection with amino acid infusions. Hematological profiles and renal function (GFR and TER) were regularly monitored after PRRT.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad

To read results and conclusion, please login ...

Further abstracts you may be interested in

#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#236 Very Long-term Follow-up (> 5 years) of Renal Function of Neuroendocrine Tumor Patients Treated with Five or More Cycles of Peptide Receptor Radionuclide Therapy (PRRNT)
Introduction: Nephrotoxicity is one of the primary concerns in neuroendocrine tumor (NET) patients (pts.) treated with peptide receptor radionuclide therapy (PRRNT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#238 Peptide Receptor Radionuclide Therapy (PRRNT) in Patients with Metastasized Neuroendocrine Tumor Having Single or Non-functional Kidney - Is it Safe?
Introduction: Nephrotoxicity is one of the primary concerns in PRRNT of metastasized neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#450 Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multiinstitutional Cancer Registry
Introduction: Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor expressing neuroendocrine tumors. However, published data results mainly from retrospective monocentric studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Dieter Hörsch
#610 Effectiveness of PRRT for NETs in Germany: An Analysis of 450 Patients
Introduction: Peptide receptor radionuclide therapy targets somatostatin receptors expressed on well-differentiated neuroendocrine neoplasms. Retrospective monocentric studies indicate that peptide receptor radionuclide therapy is an effective treatment for patients with neuroendocrine neoplasms.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Prof. Dr. Dieter Hörsch
Keywords: PRRT